| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10519146 | AMGEN INC | KRAS G12C inhibitors and methods of using the same |
May, 2038
(14 years from now) | |
| US11236091 | AMGEN INC | Solid state forms |
May, 2040
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11426404 | AMGEN INC | Dosing of KRAS inhibitor for treatment of cancers |
Sep, 2040
(16 years from now) | |
Lumakras is owned by Amgen Inc.
Lumakras contains Sotorasib.
Lumakras has a total of 3 drug patents out of which 0 drug patents have expired.
Lumakras was authorised for market use on 28 May, 2021.
Lumakras is available in tablet;oral dosage forms.
Lumakras can be used as treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy.
Drug patent challenges can be filed against Lumakras from 2025-05-28.
The generics of Lumakras are possible to be released after 15 September, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 28, 2026 |
| Orphan Drug Exclusivity (ODE) | May 28, 2028 |
Drugs and Companies using SOTORASIB ingredient
NCE-1 date: 2025-05-28
Market Authorisation Date: 28 May, 2021
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...
Dosage: TABLET;ORAL
LUMAKRAS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic